Has Nina Blum, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,553 in general payments to Nina Blum, MD across 645 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nina Blum, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nina Blum, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nina Blum, MD

Internal Medicine · Tavares, FLNPI 1922533256

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.7% of the total across 645 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Amgen at 24.0% of the total. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,553in general payments, 2019–2025

Across 645 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$3K
UCB, Inc.$1K
AbbVie$1K
Sanofi$1K
Johnson & Johnson$871
Novartis$834
plus $5K from 18 others

What the payments were for

Food & beverage$13,37499%
Education$1791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	146	$3,255
UCB, Inc.	81	$1,366
AbbVie	61	$1,161
Sanofi	22	$1,056
Johnson & Johnson	33	$871
Novartis	38	$834
Lilly USA, LLC	39	$796
Pfizer	69	$760
ANI Pharmaceuticals, Inc.	28	$635
Mallinckrodt Hospital Products Inc.	26	$441
AstraZeneca	18	$431
E.r. Squibb & Sons, L.L.C.	17	$417
Radius Health, Inc.	16	$402
GSK	22	$374
Boehringer Ingelheim	10	$238
Sobi, Inc	9	$180
Sanofi-aventis U.S. LLC	2	$179
Aurinia Pharma U.S., Inc.	2	$38
Genentech USA, Inc.	1	$25
Pacira Therapeutics, Inc.	1	$24
Ultragenyx Pharmaceutical Inc.	1	$22
Fresenius Kabi USA, LLC	1	$17
Teva Pharmaceuticals USA, Inc.	1	$16
Sandoz	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,553 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida →

Medicare billing

Part B allowed, 2024

$1,834,940

Medicare patients

551

Services billed

154,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	16	$134,238
Humira PenAdalimumab	11	$131,563
Hydroxychloroquine Sulfate	226	$12,378
MethotrexateMethotrexate Sodium	193	$6,191
Celecoxib	25	$2,289
Prednisone	203	$1,515
Leflunomide	20	$1,075
Mycophenolate Mofetil	12	$951
Duloxetine Hcl	41	$822
Alendronate Sodium	93	$758
Sulfasalazine	26	$654
Gabapentin	29	$577
Colchicine	18	$577
Methotrexate SodiumMethotrexate Sodium/Pf	28	$504
Leucovorin Calcium	36	$405

Paid to pharmacies, not to this prescriber.

Other internal medicine in Tavares

Haytham ElgammalMiami$2.2M
Keith RubinFort Lauderdale$2M
Michael SensionFort Lauderdale$1M
Quang NguyenOcala$434K
Luis Correa LunaSanford$412K
Michael OleksykFort Myers$365K
Andrew KuykendallTampa$322K
Howard FederoffCoconut Grove$302K
Bianka EperjesiovaGainesville$260K
Julio ConradoFort Myers$247K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →